Capital Investment Services Of America Has Lowered Cerner (CERN) Position By $300,495; Rare Hospitality International (RARE)’s Sentiment Is 1.25

Cerner Corporation (NASDAQ:CERN) Logo

Capital Investment Services Of America Inc decreased Cerner Corp (CERN) stake by 2.04% reported in 2017Q4 SEC filing. Capital Investment Services Of America Inc sold 4,485 shares as Cerner Corp (CERN)’s stock declined 14.44%. The Capital Investment Services Of America Inc holds 214,849 shares with $14.48 million value, down from 219,334 last quarter. Cerner Corp now has $18.99B valuation. The stock increased 3.90% or $2.15 during the last trading session, reaching $57.24. About 4.30 million shares traded or 44.30% up from the average. Cerner Corporation (NASDAQ:CERN) has declined 2.77% since May 5, 2017 and is downtrending. It has underperformed by 14.32% the S&P500.

Rare Hospitality International Inc (RARE) investors sentiment increased to 1.25 in Q4 2017. It’s up 0.06, from 1.19 in 2017Q3. The ratio increased, as 70 investment professionals increased and started new positions, while 56 sold and decreased their equity positions in Rare Hospitality International Inc. The investment professionals in our database now hold: 42.32 million shares, up from 39.75 million shares in 2017Q3. Also, the number of investment professionals holding Rare Hospitality International Inc in top ten positions decreased from 1 to 0 for a decrease of 1. Sold All: 14 Reduced: 42 Increased: 51 New Position: 19.

Iguana Healthcare Management Llc holds 1.51% of its portfolio in Ultragenyx Pharmaceutical Inc. for 50,000 shares. Opaleye Management Inc. owns 90,000 shares or 1.34% of their US portfolio. Moreover, Abingworth Llp has 1.28% invested in the company for 38,100 shares. The Illinois-based Columbia Wanger Asset Management Llc has invested 1% in the stock. Pier Capital Llc, a Connecticut-based fund reported 125,728 shares.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company has market cap of $2.71 billion. The firm is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It currently has negative earnings. The Company’s biologics product candidates also comprise recombinant human beta -glucuronidase , an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis.

More notable recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Bizjournals.com which released: “North Bay company looks for 2nd rare-disease drug approval, voucher in 5 months” on April 16, 2018, also Nasdaq.com with their article: “Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results and Corporate Update” published on May 01, 2018, Bizjournals.com published: “Peninsula drug maker swings $110 million deal for voucher” on April 30, 2018. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) were released by: Nasdaq.com and their article: “Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the US for the Treatment of X …” published on April 30, 2018 as well as Nasdaq.com‘s news article titled: “Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug Application for DTX401, a Gene …” with publication date: April 23, 2018.

The stock increased 3.49% or $1.84 during the last trading session, reaching $54.5. About 259,440 shares traded. Ultragenyx Pharmaceutical Inc. (RARE) has declined 29.39% since May 5, 2017 and is downtrending. It has underperformed by 40.94% the S&P500.

Ratings analysis reveals 0 of Ultragenyx Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Ultragenyx Pharma, 0 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. RARE was included in 2 notes of analysts from November 14, 2016. The stock has “Sell” rating by Citigroup on Monday, November 14. The firm has “Hold” rating given on Thursday, April 6 by Jefferies.

Since December 13, 2017, it had 0 insider buys, and 4 insider sales for $37.88 million activity. 4,000 Cerner Corporation (NASDAQ:CERN) shares with value of $279,560 were sold by Battaglioli Michael R.. ILLIG CLIFFORD W had sold 307,700 shares worth $19.85M on Wednesday, March 7. BURKE ZANE M also sold $3.50 million worth of Cerner Corporation (NASDAQ:CERN) shares. $14.25 million worth of Cerner Corporation (NASDAQ:CERN) was sold by TOWNSEND JEFFREY A.

Investors sentiment increased to 1.05 in Q4 2017. Its up 0.07, from 0.98 in 2017Q3. It is positive, as 42 investors sold CERN shares while 217 reduced holdings. 78 funds opened positions while 194 raised stakes. 251.96 million shares or 4.52% less from 263.89 million shares in 2017Q3 were reported. Advisory Ser Limited Liability Corp invested 0.05% in Cerner Corporation (NASDAQ:CERN). 25,820 are held by Amica Mutual Ins. Alpha Windward Ltd Com reported 2,555 shares or 0.1% of all its holdings. Fdx Advisors Inc holds 0.04% or 22,500 shares in its portfolio. Parallax Volatility Advisers Lp has invested 0% in Cerner Corporation (NASDAQ:CERN). Telemus Cap Limited Liability Company accumulated 308 shares. Douglass Winthrop Advsr Ltd Liability Com has invested 0.09% in Cerner Corporation (NASDAQ:CERN). Gradient Ltd Liability Co reported 326 shares stake. State Of Alaska Department Of Revenue holds 0.07% in Cerner Corporation (NASDAQ:CERN) or 42,735 shares. Amica Retiree invested in 0.1% or 1,992 shares. Everence has invested 0.07% in Cerner Corporation (NASDAQ:CERN). First Manhattan holds 0% or 1,292 shares. Moreover, Patten Gp Inc has 0% invested in Cerner Corporation (NASDAQ:CERN) for 40 shares. Connecticut-based Macguire Cheswick & Tuttle Inv Counsel Ltd Liability Com has invested 0.11% in Cerner Corporation (NASDAQ:CERN). Sterling Cap Mngmt Ltd Liability accumulated 774,431 shares.

Among 29 analysts covering Cerner Corporation (NASDAQ:CERN), 15 have Buy rating, 0 Sell and 14 Hold. Therefore 52% are positive. Cerner Corporation has $87 highest and $45 lowest target. $66.91’s average target is 16.89% above currents $57.24 stock price. Cerner Corporation had 114 analyst reports since August 5, 2015 according to SRatingsIntel. KeyBanc Capital Markets maintained Cerner Corporation (NASDAQ:CERN) on Wednesday, September 20 with “Buy” rating. The stock has “Buy” rating by Piper Jaffray on Thursday, October 12. The firm has “Buy” rating by Piper Jaffray given on Wednesday, November 22. Canaccord Genuity maintained Cerner Corporation (NASDAQ:CERN) rating on Thursday, July 27. Canaccord Genuity has “Buy” rating and $6900 target. The company was reinitiated on Wednesday, August 31 by Stifel Nicolaus. Cantor Fitzgerald maintained Cerner Corporation (NASDAQ:CERN) on Thursday, March 29 with “Buy” rating. Citigroup upgraded the stock to “Buy” rating in Monday, April 23 report. The company was upgraded on Thursday, June 23 by Suntrust Robinson. Robert W. Baird maintained Cerner Corporation (NASDAQ:CERN) rating on Thursday, March 8. Robert W. Baird has “Buy” rating and $75.0 target. The stock of Cerner Corporation (NASDAQ:CERN) has “Buy” rating given on Sunday, July 9 by Cantor Fitzgerald.

More notable recent Cerner Corporation (NASDAQ:CERN) news were published by: Globenewswire.com which released: “Cerner Reports First Quarter 2018 Results” on May 02, 2018, also Seekingalpha.com with their article: “Cerner -7.7% on Q1 rev. miss, downside guidance” published on May 02, 2018, Globenewswire.com published: “Cerner to Release First Quarter 2018 Earnings Results May 2” on April 16, 2018. More interesting news about Cerner Corporation (NASDAQ:CERN) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on April 23, 2018 as well as Seekingalpha.com‘s news article titled: “Cerner (CERN) Q1 2018 Results – Earnings Call Transcript” with publication date: May 03, 2018.

Cerner Corporation (NASDAQ:CERN) Institutional Positions Chart